Infectious Disease

Top Story

2015-2016 flu vaccine: What you need to know

October 6, 2015

Every winter, scientists from WHO observe which strains of influenza circulate around the world. Based on WHO’s recommendation, the CDC chooses which viruses to target in the influenza vaccine for the United States.

During the 2014-2015 flu season, the dominant H3N2 influenza strain mutated after the flu vaccine was released. The strain used for last season’s vaccine did not match the circulating strain, the CDC reported, and as a result the vaccine reduced flu visits to doctors by only 19% (95% CI, 7%-29%). Typically, the vaccine reduces flu visits by 50% to 60%, according to the CDC.

Michael Silverberg In the Journals

Individuals with HIV living long enough to develop cancer

October 6, 2015
The cumulative incidence of certain cancers has increased among individuals with HIV because they are living longer, according to data from the North American AIDS…
FDA News

FDA updates labeling for Olysio

October 6, 2015
The FDA recently announced revisions to product labeling for Olysio used in combination with ribavirin and peginterferon alfa for the treatment of adults with hepatitis…

Syphilis rate increased 50% among armed services over 5-year period

October 6, 2015
From 2010 to 2014, the rate of primary and secondary syphilis increased by 49.1% among active members of the U.S. military, according to a report from the Armed Forces…
In the Journals

Drug-induced quiescence may increase resistance in P. falciparum

October 6, 2015
Multidrug tolerance of Plasmodium falciparum to artemisinin derivatives occurs as a result of drug-induced dormancy, which facilitates the survival of parasites after…
More News Headlines »
Infectious Disease Case Consults

The Patient with Conjunctivitis

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with conjunctivitis.
More »
Meeting News Coverage Video
VIDEO: Monoclonal antibody shows promise in CDI treatment

VIDEO: Monoclonal antibody shows promise in CDI treatment

September 23, 2015
SAN DIEGO — Mark H. Wilcox, MD, FRCPath, professor of medical microbiology at Leeds Teaching Hospitals and the…
More »
Current Controversies in HIV Management:  Use of PrEP, Initial Treatment Regimens, Switching/Substitution, and Co-Infection

Evolution of HIV Treatment: How to Start, How to Switch, How to Treat HIV/HCV Co-infection

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

Improvements in antiretroviral therapy (ART) continue to be made with the development of simplified, single-tablet…
More »